Amit Rajparia
New York University
Publications 5
#1Marc W. Manseau (NYU: New York University)H-Index: 9
#2Amit Rajparia (NYU: New York University)H-Index: 4
Last.Crystal Fuller Lewis (NYU: New York University)H-Index: 6
view all 7 authors...
ABSTRACTBackground: Increasing reports of synthetic cannabinoid (SC)-related adverse events have largely comprised case reports and analyses of calls to poison control centers. Existing studies have also mostly involved white male populations. Objectives: The purpose of this study is to systematically describe clinical characteristics of SC use in a relatively large, diverse, urban sample presenting to a psychiatric emergency setting. Methods: SC users (n = 110) were identified by reviewing char...
#1Adriana Joseph (Nathan Kline Institute for Psychiatric Research)H-Index: 2
#2Marc W. Manseau (NYU: New York University)H-Index: 9
Last.Crystal Fuller Lewis (NYU: New York University)H-Index: 6
view all 5 authors...
ABSTRACTBackground: Growing evidence of adverse outcomes following synthetic cannabinoid use has engendered interest into populations at risk. The existing literature reports that synthetic cannabinoid use is predominant among young, white males. However, reports from local Departments of Health have found contrary evidence, showing that synthetic cannabinoid use is prevalent in populations other than those of young, white men. Objectives: This study sought to examine sociodemographic characteri...
Elevated peripheral proline is associated with psychiatric disorders, and there is evidence that proline is a neuromodulator. The proline dehydrogenase (PRODH) gene, which encodes the enzyme that catalyzes proline catabolism, maps to human chromosome 22q11.2, a region conferring risk of schizophrenia. In the Prodh-null mouse, an interaction between elevated peripheral proline and another 22q11.2 gene, catechol-O-methyltransferase (COMT), on neurotransmission and behavior has been reported. We ex...
#1James D. Clelland (NYU: New York University)H-Index: 8
#2Laura L. Read (NYU: New York University)H-Index: 9
Last.Catherine L. Clelland (CUMC: Columbia University Medical Center)H-Index: 8
view all 9 authors...
Abstract 25-Hydroxyvitamin D (25(OH)D) deficits have been associated with schizophrenia susceptibility and supplementation has been recommended for those at-risk. Although the mechanism by which a deficit confers risk is unknown, vitamin D is a potent transcriptional modulator and can regulate proline dehydrogenase ( PRODH ) expression. PRODH maps to chromosome 22q11, a region conferring the highest known genetic risk of schizophrenia, and encodes proline oxidase, which catalyzes proline catabol...